Concurrent TGF-β blockade might be a feasible strategy to enhance the efficacy of immunotherapy and relieve immune checkpoint inhibitor resistance [64]. Selective inhibition of TGF-β1 activation overcomes primary resistance to checkpoint blockade therapy by altering tumor immune landscape [65]. Here, TGFB1 is linked to neoplasm.